Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Anti IL-12 monoclonal antibody/ABT-874 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Anti IL-12 monoclonal antibody/ABT-874, up to 12 weeks, 200 mg every week for 12 weeks |
| 2 | ACTIVE_COMPARATOR | Anti IL-12 monoclonal antibody/ABT-874, 200 mg QOW for 12 weeks |
| 3 | ACTIVE_COMPARATOR | Anti IL-12 monoclonal antibody/ABT-874, 100 mg QOW in 12 weeks |
| 4 | ACTIVE_COMPARATOR | Anti IL-12 monoclonal antibody/ABT-874, 200 mg times 4 doses in 12 weeks |
| 5 | ACTIVE_COMPARATOR | Anti IL-12 monoclonal antibody/ABT-874, 200 mg times 1 dose in 12 weeks |
| 6 | PLACEBO_COMPARATOR | placebo, 12 doses |
| Name | Type | Description |
|---|---|---|
| Anti IL-12 monoclonal antibody/ABT-874 | DRUG | Please see Arm Description for intervention description and details. |
| placebo | DRUG | 12 doses |
Inclusion Criteria: * Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history. * Subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate to severe plaque psoriasis Exclusion Criteria: * Subject had previously rece...
Anti IL-12 monoclonal antibody/ABT-874 is an investigational drug being studied for the treatment of moderate to severe chronic plaque psoriasis. It is a small molecule in Phase 2 clinical development, and it has not been approved by regulatory authorities.
Anti IL-12 monoclonal antibody/ABT-874 targets interleukin-12 (IL-12), a cytokine involved in inflammatory and immune responses. By targeting IL-12, the drug aims to modulate the immune pathway implicated in psoriasis.
Anti IL-12 monoclonal antibody/ABT-874 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV.
Anti IL-12 monoclonal antibody/ABT-874 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency.
Anti IL-12 monoclonal antibody/ABT-874 has one completed Phase 2 trial, NCT00292396, which evaluated its efficacy and safety in 180 subjects with moderate to severe chronic plaque psoriasis. The trial was randomized, double-blind, and placebo-controlled, conducted in the United States and Canada.